Oct 6, 2025 09:00AM Editas Medicine to present EDIT-401 data at gene therapy congress

Sep 5, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Editas Medicine (EDIT)

Sep 3, 2025 05:01AM Editas Medicine (EDIT) PT Raised to $4 at Wells Fargo

Sep 2, 2025 07:03AM Editas Medicine selects EDIT-401 as lead in vivo development candidate

Aug 15, 2025 06:52AM Editas Medicine (EDIT) PT Raised to $5 at H.C. Wainwright

Aug 13, 2025 05:58AM Editas Medicine (EDIT) PT Raised to $6 at Baird

Aug 12, 2025 05:45PM Editas Medicine (EDIT) Misses Q2 EPS by 23c

Jun 18, 2025 12:15PM CRISPR Therapeutics (CRSP) gains on continued chatter

Jun 17, 2025 11:28AM Verve Therapeutics takeover has 'positive readthrough' for gene editing space - BMO Capital

May 13, 2025 07:26AM Editas Medicine (EDIT) Misses Q1 EPS by 36c

May 13, 2025 07:06AM Editas Medicine (EDIT) Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025 04:49AM Editas Medicine (EDIT) PT Lowered to $4 at Evercore ISI

May 12, 2025 04:02PM Editas Medicine (EDIT) Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

Mar 20, 2025 04:01PM Editas Medicine (EDIT) Announces CFO Change

Mar 5, 2025 04:52PM Editas Medicine (EDIT) Misses Q4 EPS by 22c

Feb 20, 2025 05:43AM Editas Medicine (EDIT) call put ratio 5.1 calls to 1 put on active option volume of 30K contracts

Jan 13, 2025 09:05AM Editas Medicine (EDIT) Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Dec 18, 2024 05:09PM Clear Street Starts Editas Medicine (EDIT) at Buy

Dec 13, 2024 12:22PM Editas Medicine (EDIT) PT Lowered to $5 at Evercore ISI

Dec 13, 2024 08:02AM Chardan Capital Markets Downgrades Editas Medicine (EDIT) to Neutral

Dec 13, 2024 07:15AM Editas Medicine (EDIT) PT Lowered to $4 at RBC Capital on Lead Program Termination

Dec 13, 2024 06:53AM Editas Medicine (EDIT) PT Lowered to $8 at Baird

Dec 13, 2024 03:29AM Stifel Downgrades Editas Medicine (EDIT) to Hold

Dec 13, 2024 03:27AM Truist Securities Downgrades Editas Medicine (EDIT) to Hold

Dec 12, 2024 04:00PM Editas Medicine (EDIT) Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 11, 2024 05:40AM Wells Fargo Downgrades Editas Medicine (EDIT) to Equal Weight

Dec 9, 2024 12:00PM Editas Medicine (EDIT) Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematolog

Nov 23, 2024 09:56AM BofA Securities Double Upgrades Editas Medicine (EDIT) to Buy

Nov 6, 2024 11:47AM Evercore ISI Upgrades Editas Medicine (EDIT) to Outperform

Nov 5, 2024 04:19PM Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)

Nov 5, 2024 12:43PM Oppenheimer Reiterates Perform Rating on Editas Medicine (EDIT)

Nov 5, 2024 06:59AM Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital

Nov 5, 2024 05:23AM Editas Medicine (EDIT) PT Lowered to $5 at Barclays

Nov 4, 2024 12:25PM Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities

Nov 4, 2024 07:45AM Editas Medicine (EDIT) Reports In-Line Q3 EPS

Oct 23, 2024 06:36AM Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo

Oct 22, 2024 01:41PM Editas Medicine (EDIT) PT Lowered to $10 at Baird

Oct 22, 2024 07:02AM Editas Medicine (EDIT) Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Oct 4, 2024 05:55AM Leerink Partners Reiterates Market Perform Rating on Editas Medicine (EDIT)

Sep 17, 2024 04:12PM Jones Trading Starts Editas Medicine (EDIT) at Buy

Aug 8, 2024 08:22AM Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities

Aug 7, 2024 07:03AM Editas Medicine (EDIT) Misses Q2 EPS by 12c